Keyphrases
Transforming Growth Factor-β
100%
Zr-89
100%
High-grade Glioma
100%
Fresolimumab
100%
Antibody Uptake
100%
PET Scan
16%
After Injection
16%
Tumor Uptake
16%
SUVmax
16%
Magnetic Resonance Imaging
8%
Treatment Outcome
8%
Monoclonal Antibody
8%
Intravenous Administration
8%
Clinical Benefit
8%
Glioblastoma
8%
Glioma
8%
Normal Brain Tissues
8%
Median Overall Survival
8%
Radiologic
8%
Response Evaluation
8%
Standardized Uptake Value
8%
Tracer Injection
8%
Anaplastic Astrocytoma
8%
Transforming Growth Factor-β Signaling
8%
Median Progression-free Survival
8%
Anaplastic Oligodendroglioma
8%
Clinically Indicated
8%
Tumor-like Lesions
8%
SUVmean
8%
Recurrent Glioma
8%
Medicine and Dentistry
Ganglioglioma
100%
Positron Emission Tomography
100%
Transforming Growth Factor Beta Antibody
100%
Fresolimumab
100%
Neoplasm
23%
Positron Emission Tomography
15%
Glioblastoma
15%
Infusion
15%
Transforming Growth Factor Beta
15%
Radioactive Tracer
7%
Monoclonal Antibody
7%
Magnetic Resonance Imaging
7%
Overall Survival
7%
Brain Tissue
7%
Progression Free Survival
7%
Standardized Uptake Value
7%
Oligodendroglioma
7%
Pharmacology, Toxicology and Pharmaceutical Science
Transforming Growth Factor Beta Antibody
100%
Fresolimumab
100%
Glioma
100%
Neoplasm
23%
Transforming Growth Factor Beta
15%
Glioblastoma
15%
Mouse
7%
Monoclonal Antibody
7%
Overall Survival
7%
Tracer
7%
Progression Free Survival
7%
Oligodendroglioma
7%